Skip to main content
Back
Activeted-495404-2026

Non-exclusive rebate agreement for Perindopril arginine + Amlodipine + Indapamide (ATC C09BX01)

Non-exclusive rebate agreement according to § 130a Abs. 8 SGB V for the active substance Perindopril arginine + Amlodipine + Indapamide (ATC C09BX01): Conclusion of a framework agreement for pharmaceutical companies under the same conditions, with a term from 01.09.2026 to 31.08.2028 and an extension option of 1x12 months. Required documents include an offer letter, acceptance of contractual terms and rebates, and completed Annexes 1 and 2. Submission of documents via email to openhouse@dak.de, Annex 2 as an Excel file. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month; later entries are possible at any time, with documents for an entry on the 1st or 15th of the following month also due by the 5th of the preceding month. This procedure is designed as an open house procedure.

View original source

CONTRACTING AUTHORITY

Name

DAK-Gesundheit

City

Hamburg

Country

DE

CLASSIFICATION

Procedure Type

Open Procedure

Contract Type

Supplies

Main CPV

33600000, Pharmaceutical products.

ADDITIONAL DETAILS

EU Funded

Yes

Suitable for SMEs

No

Electronic Submission

Required

Legal Basis

32014L0024

DEADLINES & TIMELINE

Submission Deadline

1084 days remaining

(LOT-0001)

Published

TENDER DOCUMENTS

1084 days remaining

Similar Tenders

Explore CPV 33

Discount agreement for the active ingredient Lidocaine (ATC N01BB02)

Discount agreement for the active ingredient Lidocaine (ATC N01BB02): non-exclusive according to § 130a para. 8 SGB V, with a term from 01.09.2026 to 31.08.2028 and an extension option of 1x12 months. The agreement is open to all pharmaceutical companies at any time under the same conditions. Required documents include an offer letter, acceptance of DAK-Gesundheit's contractual terms and specified discounts, and completed Annexes 1 and 2, where medicines containing Lidocaine must be listed. Submission of documents, with Annex 2 as an Excel file, is via email to openhouse@dak.de. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month; later entries for the 1st or 15th of the following month require submission by the 5th of the preceding month.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Non-exclusive rebate agreement for the active ingredient Brinzolamide + Brimonidine

Non-exclusive rebate agreement for the active ingredient Brinzolamide + Brimonidine (ATC S01EC24): Conclusion of a framework agreement for pharmaceutical companies under equal conditions, with accession possible at any time. The contract duration is from 01.09.2026 to 31.08.2028, with an extension option of 1x12 months. Required documents for contract conclusion or later accession include an offer letter, acceptance of DAK-Gesundheit's contractual terms and rebates, and completed Annexes 1 and 2 (listing the medicines to be covered). Submission of documents is via email to openhouse@dak.de, with Annex 2 to be sent as an Excel file. For a contract start on 01.09.2026 or later accession on the 1st or 15th of a month, documents must be submitted by the 5th of the preceding month. This procedure does not fall under cartel procurement law and automatically ends upon the entry into force of an exclusive contract for the active ingredient Brinzolamide + Brimonidine.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Non-exclusive discount agreement for Olanzapine (TRS dosage form), ATC N05AH03

Conclusion of non-exclusive discount agreements for the active ingredient Olanzapine (TRS dosage form only), ATC N05AH03. Any pharmaceutical company can conclude a framework agreement under the same conditions during the contract term. The contract term begins on 01.09.2026 and ends on 31.08.2028, with an extension option of 1x12 months. For contract conclusion or later accession, an offer letter, acknowledgment of contractual terms and discounts, and completed Annexes 1 and 2 (Excel file) must be submitted via email to openhouse@dak.de. For accession on 01.09.2026 or on the 1st or 15th of a subsequent month, documents must be submitted by the 5th of the preceding month. This procedure is not subject to cartel procurement law.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Rebate agreement for Biperiden (4mg)

Rebate agreement according to § 130a Abs. 8 SGB V for the active ingredient Biperiden (strength 4mg only), ATC N04AA02: Conclusion of a non-exclusive framework agreement under an open-house model, open to any pharmaceutical company under the same conditions. The contract duration is from 01.09.2026 to 31.08.2028, with an extension option of 1x12 months. Required documents include an offer letter, acceptance of contractual terms and specified rebates, and completed Annexes 1 and 2 (Annex 2 as an Excel file), to be submitted via email to openhouse@dak.de. Joining is possible at any time; for a contract start on the 1st or 15th of the following month, documents must be submitted by the 5th of the preceding month. further items as per the tender documents.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Find matching tenders automatically

With Patterno-HIT, receive relevant tenders daily, automatically filtered to your company profile.

Book Demo Now